Efficacy and Safety of Anti-interleukin 5 Receptor Therapy (Benralizumab) in Patients With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS)

Drug Reaction with eosinophilia and Systemic Symptoms (DRESS) is a rare and severe multiorgan drug reaction whose pathophysiological mechanisms underlying remain unclear, but may involve the role of several immune cells like eosinophils. iIndeed,the number of eosinophils is increased in blood and/or in organs tiisues in at least 50% of patients with DRESS. There is no specific treatment available. The standard of care is corticosteroids, but they may be inefficient or poorly tolerated. The aim of this research is to find out whether a specific treatment of the immunological response in DRESS syndrome would be useful in combination with corticosteroids to speed up the recovery from DRESS syndrome and therefore reduce the total length of your hospital stay when your illness is being managed. This a multicenter, international, prospective, interventional study, double-blinded, placebo-controlled, randomized, in two balanced parallel groups, one receiving the standard of care (topical or systemic corticosteroids, according to the severity of DRESS syndrome) and the other one corticsoteroids and a targeted therapy against eosinophils (benralizumab, already available in other eosinophilic diseases like asthma).

Start Date06 Jan 2027

Sponsor / Collaborator

AstraZeneca PLC

NCT07444567

/ RecruitingPhase 3

ROSY-F: Roll-Over Study for Participants Who Have Completed a Previous Study With Benralizumab (Fasenra) and Are Judged by the Investigator to Clinically Benefit From Continued Treatment

The rationale of the roll-over study (ROSY) is to provide continuous access to study treatment for participants who have completed or exited a parent study and are deemed appropriate for continued benralizumab treatment, as judged by the Investigator, while monitoring long-term safety and tolerability of benralizumab.

Start Date24 Jul 2026

Sponsor / Collaborator

AstraZeneca PLC

NCT07654842

/ Enrolling by invitationPhase 4

Fasenra Demonstrates Durability Over the Full 8-week Treatment Period

The goal of this observational study is to learn more about the effectiveness of benralizumab (Fasenra, 30 mg every 8 weeks) in maintaining asthma control in people with severe eosinophilic asthma.
Participants will have electronic medication monitors fitted to their usual maintenance inhaler, as well as a study-provided anti-inflammatory rescue inhaler, albuterol-budesonide (AirSupra). These monitors will track when each inhaler is used. Participants will also upload time-stamped photos of their benralizumab administration to their electronic medical records.

Start Date01 Jul 2026

Sponsor / Collaborator

Endeavor Health

[+1]

100 Clinical Results associated with Benralizumab

100 Translational Medicine associated with Benralizumab

100 Patents (Medical) associated with Benralizumab

1,067

Literatures (Medical) associated with Benralizumab

31 Dec 2026·ANNALS OF MEDICINE

Beyond biomarkers: the role of clinical factors associated with biologic therapy response in severe asthma

Article

Author: Lopez-Rodríguez, Raquel ; Cañas, José Antonio ; Rial, Manuel Jorge ; Mahíllo-Fernández, Ignacio

BACKGROUND:

Severe asthma carries a high burden and often requires biologic therapy targeting type 2 (T2) inflammation. However, treatment response is heterogeneous, and traditional biomarkers, such as blood eosinophils, fractional exhaled nitric oxide (FeNO), and total serum IgE, may not fully explain this variability .

OBJECTIVE:

To evaluate clinical and inflammatory characteristics associated with response to biologic therapies in a real-world cohort of severe asthma patients.

METHODS:

A single-center, ambispective observational study was conducted in the Allergology Department of A Coruña, Spain. Sixty-seven patients with severe uncontrolled asthma and treated with omalizumab, mepolizumab, benralizumab, dupilumab, or tezepelumab, were included. Patients were followed for ≥12 months. Clinical variables and inflammatory biomarkers were assessed at baseline, 4-6 months, and 12 months. Comparisons between biologic subgroups and logistic regression analyses were performed to identify factors associated with response.

RESULTS:

Female sex, nasal polyposis, elevated blood eosinophils, and frequent exacerbations were associated with better response to biologics. Clinical factors such as nasal polyposis and aspirin-exacerbated respiratory disease (AERD) showed a stronger association with treatment response than standard biomarkers (FeNO, blood eosinophils). The mean diagnostic delay was 12.1 years, suggesting a potential influence on therapeutic results.

CONCLUSION:

Beyond traditional biomarkers, clinical factors particulary nasal polyposis and AERD may play a key role in understanding response patterns to biologics. Incorporating these variables into clinical assessment may help support a more personalized management approach in severe asthma.

31 Dec 2026·COPD-Journal of Chronic Obstructive Pulmonary Disease

Number Needed to Treat with Biologics in Type-2 Inflammation COPD: A Systematic Review and Meta-Analysis

Review

Author: Wang, Qinqin ; Ma, Qianli

In moderate‑to‑severe chronic obstructive pulmonary disease (COPD), the number needed to treat (NNT) quantifies therapeutic benefit but remains underused for type-2-targeted biologics. This meta-analysis quantified the NNT for type-2-targeted biologics in moderate-to-severe COPD and incorporated the recent evidence on exacerbations, lung function, symptoms, health status, and responder outcomes. We searched PubMed, Embase and Web of Science through July 2025 for phase 2 or 3 RCTs of type-2targeted biologics in adults with COPD. The primary outcome was NNT for moderate-to-severe exacerbations; secondary outcomes included pre-bronchodilator forced expiratory volume in 1 s (FEV₁), St. George's Respiratory Questionnaire (SGRQ), Evaluating Respiratory Symptoms in COPD (E-RS-COPD), and responder proportions. Pooled ratios and mean differences were synthesized using fixed‑ or random‑effects models. Patient-based NNT was derived from cumulative incidence, event‑based NNT was derived from annualized exacerbation rates. Pooled NNTs were estimated under selected baseline‑risk scenarios. Under three baseline‑risk scenarios, pooled patient‑based NNTs for reducing moderate‑to‑severe COPD exacerbations were 12-17 for dupilumab and 11-16 for mepolizumab, benralizumab showed no clear reduction. Event-based NNTs at a baseline annual exacerbation rate of 1.055 per year were 3 for dupilumab and 5 for mepolizumab. Dupilumab was associated with improvements in pre-bronchodilator FEV₁, SGRQ, and E-RS-COPD. For mepolizumab, evidence across these non‑exacerbation outcomes was not consistently observed. In conclusion, pooled patient-based and event-based analyses suggest that both dupilumab and mepolizumab consistently reduce moderate-to-severe exacerbations in eosinophilic or type 2 inflammatory COPD, while improvements in lung function and patient-reported outcomes remain less consistent across biologics and warrant further validation. These findings derive from separate placebo‑controlled trials and should not be interpreted as establishing a comparative efficacy hierarchy among biologics.

31 Dec 2026·European Clinical Respiratory Journal

Characteristics of severe asthma patients with biologic treatment in the Swedish National Airway Register

Article

Author: Stridsman, Caroline ; Sundbom, Fredrik ; Emilsson, Össur Ingi ; Palm, Andreas

Background:

The Swedish National Airway Register (SNAR) includes data on asthma control, lung function, biomarkers, treatments, and comorbidities from asthma patients in primary and secondary care. This study aimed to describe patients with severe asthma receiving biologic treatment in SNAR and to explore its potential as a national registry for severe asthma.

Methods:

Patients with ongoing treatment with mepolizumab, benralizumab, reslizumab, dupilumab or tezepelumab and registered in SNAR between 2016 and 2024 were included. Demographic characteristics, asthma treatment, asthma control, lung function, type 2 biomarkers, and exacerbation history were described. Data were assessed at inclusion and at the most recent follow-up available.

Results:

A total of 416 patients were identified; 49% were female, mean age was 54.1 years, and mean BMI was 27.2. Inhaled corticosteroids were used by 94.4% of patients, while 39.2% received maintenance oral corticosteroids at inclusion. Asthma control was generally low and exacerbations were common. Patients differed across biologic classes with respect to age, comorbidities, lung function and biomarker profiles, reflecting heterogeneity. At follow-up (mean 193 days), improvements were observed in asthma control, lung function, type 2 biomarkers, and exacerbation frequency. Marked geographic variation in registry inclusion was identified, with several regions reporting no patients.

Conclusion:

SNAR enables nationwide characterization of patients with severe asthma treated with biologics in routine care. However, variation in inclusion and follow-up limits longitudinal interpretation. More standardized registration, particularly at treatment initiation, would strengthen SNAR's role in national monitoring, quality improvement and future research.

133

News (Medical) associated with Benralizumab

27 Aug 2026

·www.fiercepharma.com

Amgen, AZ’s Tezspire lands phase 3 eosinophilic esophagitis win, turning up heat on Dupixent

Amgen and AstraZeneca’s inflammatory disease drug Tezspire has clinched a phase 3 win in eosinophilic esophagitis (EoE) as the partners eye another challenge to Sanofi and Regeneron’s incumbent Dupixent. A phase 3 EoE trial for Tezspire has hit all primary and key secondary endpoints, Amgen and AZ announced Thursday. By targeting an upstream driver of inflammation, Tezspire demonstrated statistically significant improvements in both histologic remission—defined by a low count of peak eosinophils in the esophagus—and swallowing difficulties compared to placebo at week 24, according to the companies. For both Tezspire doses tested, the treatment effects on the study’s co-primary endpoints lasted through week 52, the companies added. The success from the phase 3 Crossing trial positions the anti-TSLP biologic to potentially expand into its third inflammatory disease indication beyond severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Amgen and AZ said they will share the study’s results with regulatory authorities and with the scientific community at an upcoming medical meeting. If approved, Tezspire would open a new front in its rivalry with Dupixent, which became the first medicine specifically indicated for EoE in 2022. Compared with Tezspire’s upstream targeting of TSLP, Dupixent works downstream in the immune cascade by blocking IL-4 and IL-13 signaling pathways. EoE is a chronic inflammatory disease of the esophagus, which can lead to esophageal narrowing and difficulty swallowing, known as dysphagia. The disorder is estimated to affect more than 470,000 people in the U.S., with increased prevalence in the past few years, according to Amgen and AZ. Before biologics are introduced, first-line treatment of EoE typically centers on three methods, frequently referred to as the “3Ds”—drugs, diet and dilation. For drugs, proton pump inhibitors such as omeprazole and swallowed topical corticosteroids like fluticasone are common options. During the Crossing trial, patients were allowed to remain on those background medications. “Despite the availability of first-line therapies or dietary interventions, many patients with eosinophilic esophagitis still experience substantial burden, including difficulty swallowing food, and emotional and daily-life impacts of the disease,” Arjan Bredenoord, M.D., a gastroenterologist at the Amsterdam University Medical Center in the Netherlands and primary investigator of the Crossing trial, said in an Aug. 27 statement. “The impressive results from the Crossing trial sustained over 52 weeks demonstrate that [Tezspire], taken every four weeks, could provide a new approach to treating this disease, with the potential to help more patients achieve remission and symptom improvement,” he added. In addition to the primary endpoints measured at week 24 and the key secondary endpoints evaluated at week 52, Crossing also hit other goals, including endoscopic disease features and histologic severity and extent at weeks 24 and 52, plus endoscopic response, inflammatory remission and total endoscopic remission at week 52. Tezspire’s trial win now gives AZ another shot at EoE after its anti-IL5 antibody Fasenra failed to make the cut. Back in 2022, the British pharma reported mixed results from the phase 3 Messina trial, in which Fasenra achieved better histological disease remission compared to placebo but came up short on the dysphagia symptoms metric. Besides EoE, Tezspire is undergoing phase 3 development—the Journey and Embark trials—in chronic obstructive pulmonary disease (COPD). First approved by the FDA for severe asthma in late 2021, Tezspire generated $1.9 billion in combined sales for Amgen and AZ in 2025, up from nearly $1.3 billion the year before. With a much broader label beyond inflammatory conditions affecting the airway, Dupixent brought in $17.8 billion in 2025 global sales. Meanwhile, against the backdrop of Tezspire’s first-in-class wins, drugmakers are developing more anti-TSLP agents. GSK recently launched phase 3 tests of its twice-yearly candidate felcorekibart (GSK5784283) for COPD and asthma after buying the long-acting drug in 2024. Last year, Roche licensed a TSLPxIL-33 bispecific antibody from China’s Qyuns Therapeutics in a deal potentially worth more than $1 billion. Qyuns also out-licensed a TSLPxIL-13 bispecific candidate to Windward Bio, which secured $165 million in crossover financing in May to help advance a twice-yearly anti-TSLP candidate into phase 3. Sanofi is also developing a TSLPxIL-13 bispecific nanobody called lunsekimig, which recently hit goals in a pair of midstage studies for asthma and CRSwNP.

Phase 3Clinical ResultDrug Approval

25 Aug 2026

·allsci.com

Japan approves Brinsupri as first treatment for non-cystic fibrosis bronchiectasis

Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Brinsupri (brensocatib) for non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients aged 12 years and older, making it the first approved treatment for the condition in Japan. Bridgewater, New Jersey-based Insmed Incorporated (Nasdaq: INSM) now holds approvals in the US, EU, and Japan for the oral, once-daily dipeptidyl peptidase 1 (DPP1) inhibitor, which received US FDA approval in August 2025 as the first therapy specifically indicated for NCFB. The Japan approval covers brensocatib 25 mg tablets taken once daily, with no additional biomarker or exacerbation-history qualifier — a broader label than the EU and UK, where approval requires at least two exacerbations in the prior 12 months. Brensocatib acts by reversibly inhibiting DPP1, a lysosomal cysteine protease that activates neutrophil serine proteases during neutrophil maturation in the bone marrow; blocking this upstream step reduces chronic neutrophilic airway inflammation without directly depleting circulating neutrophils. The MHLW decision is based on the Phase III ASPEN study, in which brensocatib 25 mg significantly reduced pulmonary exacerbation rates versus placebo over 52 weeks, prolonged time to first exacerbation, and increased the proportion of patients remaining exacerbation-free. Patients on the 25 mg dose also showed significantly lower lung function decline at week 52, measured by post-bronchodilator forced expiratory volume in one second (FEV1). The most common treatment-emergent adverse events occurring in at least 5% of patients were COVID-19, nasopharyngitis, cough, and headache. The news provides a boost to Insmed after development of brensocatib in hidradenitis suppurativa was discontinued after the CEDAR study failed to meet its primary endpoint. Brinsupri remains the only approved treatment specifically indicated for NCFB in the US, EU, and Japan. In the pipeline, AstraZeneca's tozorakimab, an anti-interleukin-33 monoclonal antibody that met its primary endpoint in Phase III chronic obstructive pulmonary disease exacerbation trials, has been cited by AstraZeneca management as a candidate for bronchiectasis development. AstraZeneca also tested benralizumab (Fasenra) in the eosinophilic NCFB subpopulation in the Phase III MAHALE trial, but failed to meet the primary endpoint, removing a leading biologic challenger from the near-term competitive field. Spot something wrong? Report an issue with this article

Clinical ResultPhase 3Drug Approval

12 Aug 2026

·www.biospace.com

Fasenra® (benralizumab) now approved in Canada for hypereosinophilic syndrome

New indication supported by NATRON Phase III trial where Fasenra delayed time to first flare or worsening of disease MISSISSAUGA, ON , Aug. 10, 2026 /CNW/ -- Health Canada has granted a Notice of Compliance (NOC) for Fasenra ® (benralizumab) as an add-on to standard therapy for the treatment of patients aged 12 years and older with hypereosinophilic syndrome (HES) without an identifiable non-hematologic secondary cause. 1 "Benralizumab's approval for people living with hypereosinophilic syndrome represents a new therapeutic option for this rare disorder," said Dr. Luke Chen, MD, FRCPC, MMEd, Division of Hematology, Dalhousie University. "The NATRON study showed a statistically significant decrease in flares and also addressed fatigue, an important symptom that can affect patients' quality of life." HES is a group of rare disorders characterized by persistent, significantly elevated levels of eosinophils (a type of white blood cell) in the blood and evidence of eosinophil-mediated organ or tissue damage. This may lead to progressive organ damage over time and if left untreated, may be fatal. In Canada, an estimated 2,000 to 2,500 people may be living with HES. 2 ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); "For people living with hypereosinophilic syndrome, this rare and potentially serious disease can disrupt nearly every part of daily life – from breathing and mobility to work, school and family responsibilities," said Durhane Wong-Rieger, President and CEO of the Canadian Organization for Rare Disorders. "For patients whose disease remains uncontrolled despite current treatments, Health Canada's approval represents a new treatment option for their condition." About NATRON NATRON was a phase III, multicentre, randomized, double-blind, parallel-group, placebo-controlled study evaluating the efficacy and safety of benralizumab 30 mg versus placebo administered subcutaneously every four weeks in eligible people with HES. The primary efficacy endpoint was time to first HES worsening or flare defined as HES clinical manifestations or lab abnormalities that result in an increase/burst of oral corticosteroids (OCS)≥10 mg/day for at least 2 days, or an increase or addition of new cytotoxic and/or immunosuppressive therapy or hospitalization. Participants (n=133) were randomized in a 1:1 ratio to receive benralizumab (30 mg or placebo every 4 weeks for 24 weeks Double Blind treatment period), in addition to background HES therapy. The trial successfully met the primary endpoint, as treatment with benralizumab delayed the time to first HES worsening/flare and significantly reduced the risk of HES flare compared to placebo by 65% (19.4% vs 42.4% patients who experienced disease worsening or flares; HR 0.35; 95% CI: 0.18, 0.69; P=0.0024). 3 Key secondary endpoints included the proportion of patients with HES flares during the 24-week treatment period, annualized rate of HES flares, time to first hematological relapse (defined as eosinophil count ≥1000 cells/mcL), and change from baseline to Week 24 in PROMIS Fatigue scores. The safety and tolerability pro benralizumab in the NATRON trial was consistent with the known pro the medicine. About Fasenra Fasenra is also indicated as an add-on maintenance treatment of adult patients with severe eosinophilic asthma as well as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). About AstraZeneca AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and Biopharmaceuticals, including Cardiovascular, Renal & Metabolic, and Respiratory & Immunology. In Canada, the company employs roughly 2,700 people and was recently named one of Canada's Top 100 Employers for the third consecutive year. AstraZeneca is one of Canada's leading R&D contributors across all sectors. Together with Alexion Rare Disease and Fusion Pharmaceuticals, AstraZeneca is delivering more than 180 clinical studies across Canada – in such areas as breast, lung, and urothelial cancers, COPD, acute kidney failure, and hypophosphatasia (HPP). Visit for more information. The content in this document is for Canadian audiences only. References: ___________________________ 1 AstraZeneca Canada Inc., FASENRA ® (benralizumab injection), Product Monograph. August 2026. 2 Data extrapolated from T. Pongdee, et al. Incidence and Prevalence of Hypereosinophilic Syndrome (HES) in the US: A Retrospective Claims Database Study. The Journal of Allergy and Clinical Immunology. Volume 157, Issue 2, Supplement AB245, February 2026 . 3 Ogbogu, P.U., Roufosse, F., Akuthota, P. et al. Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. Nat Med 32, 2017–2025 (2026). . SOURCE AstraZeneca Canada Inc.

Clinical ResultPhase 3Drug Approval

100 Deals associated with Benralizumab

External Link

KEGG	Wiki	ATC	Drug Bank
D09874	Benralizumab	R03DX10	DB12023

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hypereosinophilic Syndrome	Canada	AstraZeneca Canada, Inc.	10 Aug 2026
Eosinophilia	China	AstraZeneca AB	27 May 2026
Eosinophilic Fasciitis	Japan	AstraZeneca KK	18 May 2026
Granulomatosis With Polyangiitis	Japan	AstraZeneca KK	27 Dec 2024
Churg-Strauss Syndrome	United States	AstraZeneca AB	17 Sep 2024
Severe asthma	United States	AstraZeneca AB	17 Sep 2024
Eosinophilic Asthma	European Union	AstraZeneca AB	08 Jan 2018
Eosinophilic Asthma	Iceland	AstraZeneca AB	08 Jan 2018
Eosinophilic Asthma	Liechtenstein	AstraZeneca AB	08 Jan 2018
Eosinophilic Asthma	Norway	AstraZeneca AB	08 Jan 2018
Asthma	United States	AstraZeneca AB	14 Nov 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Sinusitis	NDA/BLA	United States	AstraZeneca PLC	14 Mar 2022
Eosinophilic Enteropathy	Phase 3	United States	AstraZeneca PLC	18 Jan 2022
Eosinophilic Enteropathy	Phase 3	Japan	AstraZeneca PLC	18 Jan 2022
Eosinophilic Enteropathy	Phase 3	Brazil	AstraZeneca PLC	18 Jan 2022
Eosinophilic Enteropathy	Phase 3	Italy	AstraZeneca PLC	18 Jan 2022
Eosinophilic Enteropathy	Phase 3	Netherlands	AstraZeneca PLC	18 Jan 2022
Eosinophilic Enteropathy	Phase 3	Poland	AstraZeneca PLC	18 Jan 2022
Eosinophilic Enteropathy	Phase 3	Spain	AstraZeneca PLC	18 Jan 2022
Eosinophilic Enteropathy	Phase 3	Ukraine	AstraZeneca PLC	18 Jan 2022
Eosinophilic Enteropathy	Phase 3	Vietnam	AstraZeneca PLC	18 Jan 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04191304 (NATRON, CTgov)	Phase 3	Hypereosinophilic Syndrome	134	benralizumab (Benra)	umbmbfyozm = baokjtizch eqclutqeat (wckyahxrxh, kbrjmgtnur - bmchxzplat) View more	-	10 Jul 2026
NCT04191304 (NATRON, CTgov)	Phase 3	Hypereosinophilic Syndrome	134	placebo (Placebo)	umbmbfyozm = ovospkypcc eqclutqeat (wckyahxrxh, fpykpunplx - smwrpvcehz) View more	-	10 Jul 2026
EULAR2026 \| ACR2026	Not Applicable	Churg-Strauss Syndrome	28	Benralizumab (EGPA)	evsatzziwc(wcrumvhwth) = ugfmlhlpld hgkdshzrar (nacejntcwo ) View more	Positive	11 Jun 2026
ATS2026	Not Applicable	Eosinophilic Asthma	3,270	Mepolizumab	majxaqgeyd(knsjxzsnhx) = Composite adverse events (headache, fatigue, dyspnea) were similar (HR 1.06 [95% CI 0.95-1.18; p = 0.36]) tnlvfbkqrb (nuzldvdxnk ) View more	Positive	15 May 2026
ATS2026	Not Applicable	Eosinophilic Asthma	3,270	Benralizumab		Positive	15 May 2026
NCT06465485 (STEP, ATS2026)	Phase 3	Eosinophilic Asthma	489	Benralizumab	tgysbgwgaw(cimcwxwcqe) = fybwqxtpym hcldatwqxn (inskqckevk ) View more	Positive	15 May 2026
ATS2026	Not Applicable	Eosinophilic Asthma	507	Benralizumab	abbowmrfuh(bsoyubcyhj) = gaypmxolxd ywhkqtcujm (bdncafiiby )	Positive	15 May 2026
ATS2026	Not Applicable	Severe asthma	71	Mepolizumab	hkkeuaqnkv(fddfqgdmfa) = vtxelqwpnd mvpvlpkuqd (hyjhehnjph ) View more	Positive	15 May 2026
ATS2026	Not Applicable	Eosinophilic Asthma	2,192	Benralizumab	hudkshcnlf(aqezinvweu) = tgecahmeqg gpgmiupaez (mdbmchyqfw ) View more	Positive	15 May 2026
ATS2026	Not Applicable	Eosinophilic Asthma	2,192	Dupilumab	hudkshcnlf(aqezinvweu) = btwgktivpx gpgmiupaez (mdbmchyqfw ) View more	Positive	15 May 2026
ATS2026	Not Applicable	Severe asthma	465	Biologic therapies	fwjyrqotyr(jzfguoehyl) = agjvkjpdld itmzvqorct (nfnflduhmf, 29.5 - 38.3) View more	Positive	15 May 2026
NCT03976310 (Pubmed \| Chest)	Phase 2	Eosinophilic Asthma	47	Benralizumab	lpsajbghhs(ekdkworuhk) = lftswtfsxl zojpermoyw (mpcomwmwju )	Positive	01 May 2026
NCT05384938 (FAST, Pubmed \| Front Med (Lausanne))	Phase 4	Eosinophilic Asthma	138	Benralizumab 30 mg	atvysnwztm(hxztezjzea) = xguwmycpla bqpolqdxtu (gtqkkpfnuf ) View more	Positive	20 Apr 2026

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis